Scientists from the German Cancer Research Center (DKFZ) and the University Medical Center Mannheim (UMM) successfully tested a new form of cellular immunotherapy against brain tumors in mice for the first time.
Investors often find stocks with momentum attractive because they have shown a recent trend of strong performance. The belief is that this trend may continue, offering the potential for profitable.
An innovative phase 2 clinical trial led by Dana-Farber Cancer Institute in collaboration with 10 major brain tumor centers around the country and designed to find new potential treatments for glioblastoma has reported initial results in the Journal of Clinical Oncology. While none of the three therapeutics tested so far improved overall survival of patients, this adaptive platform trial, the first of its kind in neuro-oncology, has the potential to rapidly and efficiently identify therapies that benefit patients.